incretin semaglutide Incretin-based therapy of metabolic disease Incretin-Based Therapies GLP-1 Receptor Agonists,

A meta-analysis of direct trials found consistent results favoring tirzepatide for weight reduction across doses

Month 3+: Continued weight loss, improved metabolic markers, and growing confidence in the medication

GLP-1 receptor agonists are typically prescribed when diet and exercise arent enough for weight loss

Common Side Effects of Semaglutide 7.1 Gastrointestinal Symptoms (Nausea, Vomiting, Diarrhea) 7.2 Appetite Suppression and Early Satiety 7.3 Fatigue and Mild Weakness 7.4 Injection Site Reactions Mild erythema or discomfort at the injection site may occur but is usually self-limiting

These adjustments should follow standard escalation timing rather than impulsive changes